These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25102328)

  • 1. A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept.
    Tek C; Ratliff J; Reutenauer E; Ganguli R; O'Malley SS
    J Clin Psychopharmacol; 2014 Oct; 34(5):608-12. PubMed ID: 25102328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial.
    Tek C; Guloksuz S; Srihari VH; Reutenauer EL
    BMC Psychiatry; 2013 Jun; 13():176. PubMed ID: 23805859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain.
    Barak N; Beck Y; Albeck JH
    J Clin Psychopharmacol; 2016 Jun; 36(3):253-6. PubMed ID: 27028981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.
    Taveira TH; Wu WC; Tschibelu E; Borsook D; Simonson DC; Yamamoto R; Langleben DD; Swift R; Elman I
    J Psychopharmacol; 2014 Apr; 28(4):395-400. PubMed ID: 24218048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
    Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
    Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study.
    de Silva VA; Dayabandara M; Wijesundara H; Henegama T; Gunewardena H; Suraweera C; Hanwella R
    J Psychopharmacol; 2015 Dec; 29(12):1255-61. PubMed ID: 26510448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
    Correll CU; Newcomer JW; Silverman B; DiPetrillo L; Graham C; Jiang Y; Du Y; Simmons A; Hopkinson C; McDonnell D; Kahn RS
    Am J Psychiatry; 2020 Dec; 177(12):1168-1178. PubMed ID: 32791894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
    Jarskog LF; Hamer RM; Catellier DJ; Stewart DD; Lavange L; Ray N; Golden LH; Lieberman JA; Stroup TS;
    Am J Psychiatry; 2013 Sep; 170(9):1032-40. PubMed ID: 23846733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.
    Henderson DC; Fan X; Copeland PM; Borba CP; Daley TB; Nguyen DD; Zhang H; Hayden D; Freudenreich O; Cather C; Evins AE; Goff DC
    Acta Psychiatr Scand; 2007 Feb; 115(2):101-5. PubMed ID: 17244173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
    J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
    Henderson DC; Copeland PM; Daley TB; Borba CP; Cather C; Nguyen DD; Louie PM; Evins AE; Freudenreich O; Hayden D; Goff DC
    Am J Psychiatry; 2005 May; 162(5):954-62. PubMed ID: 15863798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers.
    Silverman BL; Martin W; Memisoglu A; DiPetrillo L; Correll CU; Kane JM
    Schizophr Res; 2018 May; 195():245-251. PubMed ID: 29158012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.
    Smith RC; Maayan L; Wu R; Youssef M; Jing Z; Sershen H; Szabo V; Meyers J; Jin H; Zhao J; Davis JM
    Psychopharmacology (Berl); 2018 Dec; 235(12):3545-3558. PubMed ID: 30382354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study.
    Hermes G; Hyman SM; Fogelman N; Kosten TR; Sinha R
    Am J Addict; 2019 Nov; 28(6):480-488. PubMed ID: 31448846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.
    Kinon BJ; Lipkovich I; Edwards SB; Adams DH; Ascher-Svanum H; Siris SG
    J Clin Psychopharmacol; 2006 Apr; 26(2):157-62. PubMed ID: 16633144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive α-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study.
    Kim NW; Song YM; Kim E; Cho HS; Cheon KA; Kim SJ; Park JY
    Int Clin Psychopharmacol; 2016 Sep; 31(5):265-74. PubMed ID: 27276401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil.
    Nasrallah HA; Aquila R; Stanford AD; Jamal HH; Weiden PJ; Risinger R
    Psychopharmacol Bull; 2017 Aug; 47(3):35-43. PubMed ID: 28839338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis.
    de Silva VA; Suraweera C; Ratnatunga SS; Dayabandara M; Wanniarachchi N; Hanwella R
    BMC Psychiatry; 2016 Oct; 16(1):341. PubMed ID: 27716110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.
    Ishøy PL; Knop FK; Broberg BV; Bak N; Andersen UB; Jørgensen NR; Holst JJ; Glenthøj BY; Ebdrup BH
    Diabetes Obes Metab; 2017 Feb; 19(2):162-171. PubMed ID: 27717222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.